Share on

Global Uterine Cancer Therapeutics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type, Therapy and Region – Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 1410
Pages: 184
Formats: report pdf report excel report power bi report ppt

Uterine Cancer Therapeutics Market Size (2022 to 2027)

The size of the Global Uterine Cancer Therapeutics Market is estimated to be growing at a CAGR of 5.45% from 2022 to 2027. The size of the market is estimated to be USD 26.6 billion by 2027 from USD 20.4 billion in 2022.

During the forecast period, the global Uterine Cancer Therapeutics Market is estimated to hike at a promising growth rate due to the widening awareness of uterine cancer and increasing healthcare expenditure. In the United States, September is Gynecologic Cancer Awareness Month. The American Association for Cancer Research has stated that endometrial carcinoma is prevalent globally, whereas Uterine Sarcoma is a rare cancer type. CDC has affirmed that around 68% of the uterine cancers are endometrial carcinomas.

Besides, developing nations like India have a National Cancer Control Programme founded in 1975–76. It has added to the expansion of Regional Cancer Centres (RCCs), oncology departments in medical institutes, and aid for teletherapy machines' purchase. Further, awareness programs about cancer are being conducted, creating awareness among women about uterine cancer's severity.

After studying the disease's critical nature and its importance, healthcare providers and the governments are introducing awareness programs in several areas such as North America, Europe, and Asia-Pacific. With increasing government and the healthcare providers' focus, it has been indicated that the market will increase during the forecast period.


Increasing healthcare expenditure, rising focus of government to provide adequate healthcare solutions, growing advancements in the cancer screening & treatment methods, an increasing number of newly diagnosed uterine cancer cases are driving the growth of the global Uterine Cancer Therapeutics market. Besides, increasing advancements in the molecular diagnostics industry to support target specific therapies and rising awareness among patients is further stimulating the global Uterine Cancer Therapeutics market.

There is a growing awareness of the prevalence of uterine cancer among both physicians and health care providers, who are now learning more deeply about the treatments available to treat these diseases. It is among the leading drivers of uterine cancer therapy and diagnosis on the global market. Also, massive increases in urban healthcare expenditures and initiatives by different governments to improve their healthcare infrastructure fuel the uterine cancer therapy and diagnosis market. Besides, advances in medical innovation and the launch of new drugs for uterine cancer encourage patients' investment in proper treatment.


In particular, some of the factors that are likely to impede global market growth in uterine cancer therapy and diagnosis are the low success rate of cancer drug clinical trials, expensive treatment methods, adverse side effects, and severe toxicity of these medications.

Impact of COVID-19 pandemic on Uterine Cancer Therapeutics Market:

The COVID-19 pandemic has negatively affected many countries across the globe. Several measures introduced to deal with the pandemic, such as lockdowns, reduction in trade activities, and shutdown of multiple factories and workplaces in several countries, could save lives; however, these measures have wide-ranging economic effects inducing economic contagion. Along with the risk of a slowdown of global growth, the results of COVID-19 are adversely affecting various economic sectors in economies across the globe.

Key manufacturing segments have halted operations across the globe in response to the lockdown regulations issued by governments of various countries and discontinuing public transport services.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Type, Therapy and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Market Leaders Profiled

Abbott Laboratories, Ariad Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare GmbH & Takeda Pharmaceutical Company Ltd.


This research report on the global uterine cancer therapeutics market has been segmented and sub-segmented based on the type, therapy, and region.

Uterine Cancer Therapeutics Market – By Type:

  • Uterine Sarcoma
  • Endometrial Carcinoma
    • Adenocarcinoma
    • Carcinosarcoma
    • Squamous cell carcinoma
    • Others

Based on type, the Endometrial Carcinoma segment is expected to hold the largest market share throughout the forecast period. According to, the most frequent type of cancer found in women is endometrial adenosarcoma, and about 75-80% of uterine cancers are adenocarcinomas, which differ in severity. Increasing female obesity is considered a key factor accountable for the rising incidence of endometrium carcinoma, as about 90 percent of uterine cancers affect the endometrium. With the increasing prevalence of the disease and growing awareness of the disease, substantial segment growth is expected to occur in the near future.

Uterine Cancer Therapeutics Market – By Therapy:

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Hormone Therapy

Based on therapy, the segment of Immunotherapy is projected to be the fastest-growing segment during the forecast period.

Uterine Cancer Therapeutics Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

The Global Uterine Cancer Therapeutics Market is expected to be dominated by North America shortly. The primary reason for market growth in this region is the increasing disease incidence and growing awareness among the general population. Furthermore, rapid diagnostic technological advances and quicker adoption of new technologies in the nation are causing the overall growth of the studied market.

The generality of endometrial cancer is much more considerable in developed nations such as the United States and North America, and the United Kingdom, according to recent World Health Organization (WHO) surveys. In the European region, this is a consequence of changing women's lifestyles in all these countries. The prevalence of uterine cancer in women over 50 years of age is more severe. It has also been disclosed that in developing nations such as India and China, the occurrence of cervical cancer is higher, making up for 80% of the total incidence.


Companies leading the global uterine cancer therapeutics market profiled in the report are Abbott Laboratories, Ariad Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare GmbH, and Takeda Pharmaceutical Company Ltd.


In August 2018, Merck & Co. Inc, in collaboration with Eisai Co., Ltd, received the Breakthrough Therapy designation from the US FDA to combine lenvatinib (Lenvima) pembrolizumab (Keytruda) for the treatment of patients with endometrial cancer. This designation enables the company to all fast track designation features.

In April 2018, the Swiss authority for the licensing and monitoring of therapeutic products (Swissmedic) approved Roche's Alecensa (alectinib) as a first-line treatment for patients with advanced or metastatic ALK (anaplastic lymphoma kinase)-positive, non-small cell lung cancer (NSCLC). 

In November 2017, The U.S. FDA approved Roche's skin cancer drug Zelboraf for treatment of patients with Erdheim-Chester Disease, a rare type of blood cancer.

In May 2017, Merck & Co. Inc received the US FDA approval for pembrolizumab (Keytruda) to treat tumors with specific genetic changes, including endometrial cancer. For the first time, the FDA has approved a drug based on genetic differences. The main reason behind the approval of Keytruda was for the new indication using accelerated approval and priority review to speed up the availability of drugs in treating severe diseases.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample